Allon Therapeutics Inc.
NPCUF
$0.0001
$0.000.00%
OTC PK
| 03/31/2013 | 12/31/2012 | 09/30/2012 | 06/30/2012 | 03/31/2012 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 2.63M | 2.80M | 2.69M | 2.80M | 2.70M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 9.09M | 10.82M | 11.53M | 12.62M | 12.56M |
| Operating Income | -9.09M | -10.82M | -11.53M | -12.62M | -12.56M |
| Income Before Tax | -13.24M | -14.95M | -11.65M | -12.84M | -12.65M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -13.24 | -14.95 | -11.65 | -12.84 | -12.65 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -13.24M | -14.95M | -11.65M | -12.84M | -12.65M |
| EBIT | -9.09M | -10.82M | -11.53M | -12.62M | -12.56M |
| EBITDA | -8.72M | -10.33M | -11.01M | -12.10M | -12.03M |
| EPS Basic | -0.10 | -0.12 | -0.11 | -0.13 | -0.15 |
| Normalized Basic EPS | -0.04 | -0.06 | -0.07 | -0.08 | -0.09 |
| EPS Diluted | -0.10 | -0.12 | -0.11 | -0.13 | -0.15 |
| Normalized Diluted EPS | -0.04 | -0.06 | -0.07 | -0.08 | -0.09 |
| Average Basic Shares Outstanding | 538.08M | 497.54M | 450.76M | 388.99M | 352.01M |
| Average Diluted Shares Outstanding | 538.08M | 497.54M | 450.76M | 388.99M | 352.01M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |